Spira AI, Tu H, Aggarwal S, et al. - Researchers report the outcomes of the largest retrospective observational analysis assessing KRAS p.G12C [codon 12 glycine-to-cysteine substitution of Kirsten rat sarcoma viral oncogene homolog] mutation in patients suffering from advanced non–small-cell lung cancer (NSCLC). Using a US clinico-genomic database, participants were selected. Adults experiencing advanced NSCLC (All Advanced NSCLC cohort) as well as subcohorts having different mutation profiles (KRAS p.G12C [G12C] and KRAS/epidermal growth factor receptor/anaplastic lymphoma kinase wild type [Triple WT]) diagnosed January 2011 to March 2019 were included. Similar demographics were seen across cohorts, the G12C cohort had more smokers and nonsquamous cell carcinoma histology. Among G12C patients, median real-world overall survival was estimated to be 12.0, 9.5, and 6.7 months following the first, second, and third line of therapy, respectively; median real-world progression-free survival was noted to be 5.0, 4.0, and 3.1 months. Findings revealed that presence of KRAS p.G12C mutation was associated with poor outcomes in patients with advanced NSCLC, suggesting an unmet need for more effective novel treatments.